This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
American Well (AMWL) Soars 5.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
American Well (AMWL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
The Zacks Analyst Blog Highlights Hims & Hers Health, Teladoc Health and American Well
by Zacks Equity Research
HIMS accelerates global growth with ZAVA buyout, Canadian launch, and soaring EPS estimates pointing to 177.8% upside.
Hims & Hers Paves the Way for Global Digital Health Expansion
by Debanjana Dey
HIMS accelerates its global push with the ZAVA acquisition and a planned Canada launch targeting affordable obesity care.
Hims & Hers Stock Surges 90.4% in 3 Months: What's Fueling the Rally?
by Debanjana Dey
HIMS benefits from strong online revenue, subscriber growth, and global expansion moves to fuel its health platform momentum. However, challenges may hurt performance.
Why Fast-paced Mover American Well (AMWL) Is a Great Choice for Value Investors
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, American Well (AMWL) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Does DOCS' Shift Toward Enterprise Offerings Signal a Long-Term Pivot?
by Indrajit Bandyopadhyay
DOCS sharpens its enterprise focus with AI and workflow tools, signaling a deeper pivot beyond pharma marketing roots.
BlackSky Technology (BKSY) Surges 11.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
BlackSky Technology (BKSY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Adeia (ADEA) Moves 5.2% Higher: Will This Strength Last?
by Zacks Equity Research
Adeia (ADEA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zeta (ZETA) Surges 12.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Zeta (ZETA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Lemonade (LMND) Moves 9.4% Higher: Will This Strength Last?
by Zacks Equity Research
Lemonade (LMND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?
by Zacks Equity Research
Tango Therapeutics (TNGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Evolent Health (EVH) Stock Jumps 6.9%: Will It Continue to Soar?
by Zacks Equity Research
Evolent Health (EVH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Strength Seen in Wendy's (WEN): Can Its 6.0% Jump Turn into More Strength?
by Zacks Equity Research
Wendy's (WEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Granite Ridge Resources, Inc. (GRNT) Surges 6.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Granite Ridge Resources, Inc. (GRNT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
GXO Logistics (GXO) Soars 12.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
GXO Logistics (GXO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Hims & Hers Stock Jumps 85.1% in 3 Months: Is It a Buy Now?
by Debanjana Dey
HIMS accelerates global growth with ZAVA deal, AI investments and expanded access to obesity care treatments. However, macro challenges may hurt performance.
HIMS' Buyouts Fuel International Expansion & Digital Health Innovation
by Zacks Equity Research
Hims & Hers accelerates European growth with new ZAVA acquisition, adding localized care and lab testing innovation.
Hims & Hers vs. Amwell: Which Telehealth Stock Is the Better Buy?
by Debanjana Dey
HIMS targets personalized, AI-powered care with bold obesity moves, while AMWL bets on system-wide integration via Converge and top-tier health alliances. Who wins? Let's see.
All You Need to Know About American Well (AMWL) Rating Upgrade to Buy
by Zacks Equity Research
American Well (AMWL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Does American Well (AMWL) Have the Potential to Rally 46.51% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 46.5% upside potential for American Well (AMWL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is American Well (AMWL) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how American Well Corporation (AMWL) and Claritev Corporation (CTEV) have performed compared to their sector so far this year.
American Well (AMWL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for American Well (AMWL) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
American Well Corporation (AMWL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
American Well (AMWL) delivered earnings and revenue surprises of 44.01% and 11.18%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Compared to Estimates, American Well (AMWL) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for American Well (AMWL) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
American Well Corporation (AMWL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
American Well (AMWL) delivered earnings and revenue surprises of 1.77% and 6.67%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?